295 related articles for article (PubMed ID: 30358896)
1. Andexanet alfa-The first 150 days.
Culbreth SE; Rimsans J; Sylvester K; Pallin DJ; Connors JM
Am J Hematol; 2019 Jan; 94(1):E21-E24. PubMed ID: 30358896
[No Abstract] [Full Text] [Related]
2. Coordinating emergent procedures after andexanet alfa.
Culbreth SE; Sylvester KW; Rimsans J; Connors JM
Am J Hematol; 2019 Oct; 94(10):E278-E282. PubMed ID: 31342554
[No Abstract] [Full Text] [Related]
3. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
4. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
[TBL] [Abstract][Full Text] [Related]
5. Andexanet Alfa: Considerations and Practical Applications.
Owusu KA; Effendi MK; DeFilippo NA; Reardon DP; Ian Lee A
Crit Pathw Cardiol; 2019 Dec; 18(4):200-206. PubMed ID: 31725512
[No Abstract] [Full Text] [Related]
6. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
7. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Pollack CV
Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
[No Abstract] [Full Text] [Related]
8. Real-world utilization of andexanet alfa.
Brown CS; Scott RA; Sridharan M; Rabinstein AA
Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
[TBL] [Abstract][Full Text] [Related]
9. Key Points to Consider When Evaluating Andexxa for Formulary Addition.
Peled H; Dau NQ; Lau H
Neurocrit Care; 2020 Aug; 33(1):20-24. PubMed ID: 31641937
[No Abstract] [Full Text] [Related]
10. Andexanet Alfa: First Global Approval.
Heo YA
Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
[TBL] [Abstract][Full Text] [Related]
11. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
12. Andexxa--an antidote for apixaban and rivaroxaban.
Med Lett Drugs Ther; 2018 Jun; 60(1549):99-101. PubMed ID: 29913471
[No Abstract] [Full Text] [Related]
13. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
[TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage.
Takasaki K; Hehir D; Raffini L; Samelson-Jones BJ; Shih E; Dain AS
Pediatr Blood Cancer; 2022 Jun; 69(6):e29484. PubMed ID: 34811876
[No Abstract] [Full Text] [Related]
15. Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Milling TJ; Kaatz S
Am J Med; 2016 Nov; 129(11S):S80-S88. PubMed ID: 27575436
[TBL] [Abstract][Full Text] [Related]
16. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Reversal of Direct Oral Anticoagulants.
Farina N; Miller JT
Crit Care Nurs Q; 2018; 41(2):121-128. PubMed ID: 29494368
[TBL] [Abstract][Full Text] [Related]
18. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
[TBL] [Abstract][Full Text] [Related]
19. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
20. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Darius H
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
